Posted by Michael Wonder on 17 Sep 2024
FDA approves pembrolizumab with chemotherapy for unresectable advanced or metastatic malignant pleural mesothelioma
17 September 2024 - Today, the FDA approved pembrolizumab (Keytruda, Merck) with pemetrexed and platinum chemotherapy as first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma.
Efficacy was investigated in KEYNOTE-483, a randomised, open-label trial in patients with unresectable advanced or metastatic malignant pleural mesothelioma and no prior systemic therapy for advanced/metastatic disease.
